Answers are grounded in this paper and cite their sources.
Case report reveals poor outcomes in SMARCA4-deficient gastric cancer, suggesting enhanced screening and treatment options.
SMARCA4-deficient gastric cancer is an extremely rare and aggressive subtype that has been reported periodically since 2016. Currently, only 29 cases of this alteration in gastric cancer are documented in the literature. These are characterized by low differentiation, intense invasiveness, and shorter survival periods. Consequently, the majority of these cases progress to advanced stages and, hence, often result in dismal outcomes. We report a case of a 50-year-old woman diagnosed with locally advanced SMARCA4-deficient gastric cancer. The immunohistochemical profile of the patient was positive for epithelial markers, along with the absence of human epidermal growth factor receptor 2 and microsatellite instability. The patient was advised of the 5-flurouracil, oxaliplatin, taxane (FLOT) regimen as neoadjuvant chemotherapy, and a partial response was achieved following three cycles. The tumor was declared inoperable, and consequently, the patient was continued on the FLOT regimen. After the fourth cycle, the patient's disease progressed, and eventually, the patient succumbed to it. This case report emphasizes the significance of recognizing SMARCA4 deficiency in undifferentiated gastric cancers and highlights its association with poor prognosis. The proclivity of these tumors to develop rapid resistance to chemotherapy is a major contributing factor that restricts response to conventional treatment. Drawing the attention of health care providers toward this rare cytogenetic abnormality may help in facilitating better screening techniques, as well as treatment options for this disease.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: